Naunyn-Schmiedeberg's Archives of Pharmacology · Nov 17, 2026
Perioperative pulmonary aspiration reports associated with GLP-1 receptor agonists: a pharmacovigilance analysis of FAERS
By Akhtar S, Shaukat MT, Abid M et al.
Glucagon-like peptide − 1 receptor agonists (GLP-1 RAs) are increasingly prescribed for the treatment of type 2 diabetes and obesity. Although these agents provide substantial metabolic and cardiovascular benefits, they also delay gastric emptying, which may increase the risk of perioperative pulmonary aspiration during anesthesia. Real-world evidence evaluating this potential safety concern remains limited. We conducted a retrospective pharmacovigilance study using reports from the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) from January 2016 through March 2024. A perioperative-enriched cohort was identified by restricting reports to those listing general anesthetic or neuromuscular blocking agents as surrogate markers of a perioperative setting. Patients were classified into three mutually exclusive groups: GLP-1 receptor agonists, sodium-glucose cotransporter-2 (SGLT-2) inhibitors as an active comparator, and a background surgical population. Pulmonary aspiration events were identified using MedDRA preferred terms. Disproportionality analyses were performed using reporting odds ratios (RORs), and Firth penalized multivariable logistic regression was used to evaluate independent predictors of aspiration after adjustment for age, sex, and concomitant opioid use, because exposed events were sparse. After deduplication, a total of 41,308 unique perioperative reports were identified, including 158 reports involving GLP-1 receptor agonists and 174 involving SGLT-2 inhibitors. Pulmonary aspiration showed non-significantly higher reporting odds among GLP-1 RA users (ROR 1.27, P = 0.56). In the Firth penalized adjusted analysis, GLP-1 RA exposure was associated with numerically higher, but statistically non-significant, adjusted reporting odds of pulmonary aspiration (aOR 2.08; P = 0.185). SGLT-2 inhibitor exposure showed numerically lower but statistically non-significant reporting odds of pulmonary aspiration than the background cohort (aOR 0.27; P = 0.059); this estimate rests on a single event and should not be interpreted as a protective effect. Concomitant opioid use was independently associated with aspiration (aOR 2.12; P < 0.001). In this perioperative-enriched FAERS analysis, neither the unadjusted disproportionality analysis nor the adjusted model demonstrated a statistically significant association between GLP-1 receptor agonist exposure and pulmonary aspiration, although a non-significant numerical trend was observed. Given the small number of events and the inherent limitations of spontaneous reporting data, these findings are hypothesis-generating, require prospective validation, and should not on their own guide individual perioperative decision-making.